Skip to main content

Advertisement

SpringerLink
Log in

Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the antiproliferative and antiangiogenic properties of fisetin in vitro and in vivo.

Methods

Fisetin cytotoxicity was evaluated using Lewis lung carcinoma cells (LLC), endothelial cells and NIH 3T3 cells. Endothelial cell (EC) migration and capillary-like structure formation were evaluated using EAhy 926 cells. In vivo tumour growth inhibition studies were performed using LLC-bearing mice treated with fisetin and/or cyclophosphamide (CPA).

Results

The fisetin IC50 was 59 μM for LLC and 77 μM for EC cells, compared to 210 μM for normal NIH 3T3 cells (24 h). Fisetin inhibited EC migration and capillary-like structure formation at non-cytotoxic concentrations (22–44 μM). In mice, fisetin inhibited angiogenesis assessed using the Matrigel plug assay. In LLC-bearing mice, fisetin produced a 67% tumour growth inhibition (223 mg/kg, intraperitoneal), similar to the 66% produced by low-dose CPA (30 mg/kg, subcutaneous). When fisetin and CPA were combined, however, a marked improvement in antitumour activity was observed (92% tumour growth inhibition), with low systemic toxicity. Tumour histology showed decreased microvessel density with either fisetin or CPA alone, and a dramatic decrease after the fisetin/CPA combination.

Conclusions

We have shown that fisetin not only displays in vitro and in vivo antiangiogenic properties, but also can markedly improve the in vivo antitumour effect of CPA. We propose that this drug combination associating a non-toxic dietary flavonoid with a cytotoxic agent could advantageously be used in the treatment of solid tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Kerbel RS (2008) Molecular origins of cancer: tumor angiogenesis. N Engl J Med 358:2039–2049

    Article  PubMed  CAS  Google Scholar 

  2. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31

    Article  PubMed  CAS  Google Scholar 

  3. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257

    Article  PubMed  CAS  Google Scholar 

  4. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936

    Article  PubMed  CAS  Google Scholar 

  5. Taraboletti G, Margosio B (2001) Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 1:378–384

    Article  PubMed  CAS  Google Scholar 

  6. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423–435

    Article  PubMed  CAS  Google Scholar 

  7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  8. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–3705

    Article  PubMed  CAS  Google Scholar 

  9. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799

    Article  PubMed  CAS  Google Scholar 

  10. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3:768–780

    Article  PubMed  CAS  Google Scholar 

  11. Lopez-Lazaro M (2002) Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem Anticancer Agents 2:691–714

    Article  PubMed  CAS  Google Scholar 

  12. Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751

    PubMed  CAS  Google Scholar 

  13. Havsteen BH (2002) The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96:67–202

    Article  PubMed  CAS  Google Scholar 

  14. Hill S, Williams KB, Denekamp J (1989) Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol 25:1419–1424

    Article  PubMed  CAS  Google Scholar 

  15. Touil YS, Fellous A, Scherman D, Chabot GG (2009) Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization. Nutr Cancer 61:310–321

    Article  PubMed  CAS  Google Scholar 

  16. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N (2000) Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 130:2243–2250

    PubMed  CAS  Google Scholar 

  17. Kimira M, Arai Y, Shimoi K, Watanabe S (1998) Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol 8:168–175

    PubMed  CAS  Google Scholar 

  18. Woodman OL, Chan EC (2004) Vascular and anti-oxidant actions of flavonols and flavones. Clin Exp Pharmacol Physiol 31:786–790

    Article  PubMed  CAS  Google Scholar 

  19. Park HH, Lee S, Oh JM, Lee MS, Yoon KH, Park BH, Kim JW, Song H, Kim SH (2007) Anti-inflammatory activity of fisetin in human mast cells (HMC-1). Pharmacol Res 55:31–37

    Article  PubMed  CAS  Google Scholar 

  20. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R, Schweigerer L (1997) Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 57:2916–2921

    PubMed  CAS  Google Scholar 

  21. Lee WR, Shen SC, Lin HY, Hou WC, Yang LL, Chen YC (2002) Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca2+-dependent endonuclease. Biochem Pharmacol 63:225–236

    Article  PubMed  CAS  Google Scholar 

  22. Kuntz S, Wenzel U, Daniel H (1999) Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr 38:133–142

    Article  PubMed  CAS  Google Scholar 

  23. Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM, Yang LL (2002) Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 76:351–359

    Article  PubMed  CAS  Google Scholar 

  24. Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH (2006) Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 9:68–76

    Article  PubMed  CAS  Google Scholar 

  25. Lu X, Jung J, Cho HJ, Lim DY, Lee HS, Chun HS, Kwon DY, Park JH (2005) Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr 135:2884–2890

    PubMed  CAS  Google Scholar 

  26. Sung B, Pandey MK, Aggarwal BB (2007) Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 71:1703–1714

    Article  PubMed  CAS  Google Scholar 

  27. Lu H, Chang DJ, Baratte B, Meijer L, Schulze-Gahmen U (2005) Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem 48:737–743

    Article  PubMed  CAS  Google Scholar 

  28. Olaharski AJ, Mondrala ST, Eastmond DA (2005) Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin. Mutat Res/Gene Toxicol Environ Mutagen 582:79–86

    Article  CAS  Google Scholar 

  29. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R (1995) Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 58:217–225

    Article  PubMed  CAS  Google Scholar 

  30. Jankun J, Selman SH, Aniola J, Skrzypczak-Jankun E (2006) Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment. Oncol Rep 16:341–346

    PubMed  CAS  Google Scholar 

  31. Böhl M, Tietze S, Sokoll A, Madathil S, Pfennig F, Apostolakis J, Fahmy K, Gutzeit HO (2007) Flavonoids affect actin functions in cytoplasm and nucleus. Biophys J 93:2767–2780

    Article  PubMed  Google Scholar 

  32. Khan N, Asim M, Afaq F, Abu ZM, Mukhtar H (2008) A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 68:8555–8563

    Article  PubMed  CAS  Google Scholar 

  33. Salmela AL, Pouwels J, Varis A, Kukkonen AM, Toivonen P, Halonen PK, Perala M, Kallioniemi O, Gorbsky GJ, Kallio MJ (2009) Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. Carcinogenesis 30:1032–1040

    Article  PubMed  CAS  Google Scholar 

  34. Edgell CJ, McDonald CC, Graham JB (1983) Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A 80:3734–3737

    Article  PubMed  CAS  Google Scholar 

  35. Abramoff MD, Magelhaes PJ, Ram SJ (2004) Image processing with ImageJ. Biophotonics Int 11:36–42

    Google Scholar 

  36. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731–2735

    PubMed  CAS  Google Scholar 

  37. Ding Q, Kestell P, Baguley BC, Palmer BD, Paxton JW, Muller G, Ching LM (2002) Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother Pharmacol 50:186–192

    Article  PubMed  CAS  Google Scholar 

  38. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51:43–52

    Article  PubMed  CAS  Google Scholar 

  39. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886

    PubMed  CAS  Google Scholar 

  40. Kraling BM, Razon MJ, Boon LM, Zurakowski D, Seachord C, Darveau RP, Mulliken JB, Corless CL, Bischoff J (1996) E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 148:1181–1191

    PubMed  CAS  Google Scholar 

  41. Shia CS, Tsai SY, Kuo SC, Hou YC, Chao PD (2009) Metabolism and pharmacokinetics of 3, 3′, 4′, 7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J Agric Food Chem 57:83–89

    Article  PubMed  CAS  Google Scholar 

  42. Fang SH, Hou YC, Chang WC, Hsiu SL, Chao PD, Chiang BL (2003) Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci 74:743–756

    Article  PubMed  CAS  Google Scholar 

  43. Massaad L, de Waziers I, Ribrag V, Janot F, Beaune PH, Morizet J, Gouyette A, Chabot GG (1992) Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems. Cancer Res 52:6567–6575

    PubMed  CAS  Google Scholar 

  44. Joussen AM, Rohrschneider K, Reichling J, Kirchhof B, Kruse FE (2000) Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids. Exp Eye Res 71:483–487

    Article  PubMed  CAS  Google Scholar 

  45. Kakeji Y, Teicher BA (1997) Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15:39–48

    Article  PubMed  CAS  Google Scholar 

  46. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

    Article  PubMed  CAS  Google Scholar 

  47. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD (1993) Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122:673–684

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by the Institut national de la santé et de la recherche médicale (INSERM), by the Centre national de la recherche scientifique (CNRS), by the Institut Fédératif de Recherche (IFR-71) of the Université Paris Descartes, and by a grant from the Institut National du Cancer (National Cancer Institute of France, F-92513 Boulogne-Billancourt Cedex, France).

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Paris Descartes University, Chimie ParisTech, Chemical, Genetic and Imaging Pharmacology Laboratory (INSERM U1022, CNRS UMR 8151), 4 avenue de l’Observatoire, 75006, Paris, France

    Yasmine S. Touil, Johanne Seguin, Daniel Scherman & Guy G. Chabot

Authors
  1. Yasmine S. Touil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johanne Seguin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Scherman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guy G. Chabot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guy G. Chabot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Touil, Y.S., Seguin, J., Scherman, D. et al. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol 68, 445–455 (2011). https://doi.org/10.1007/s00280-010-1505-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1505-8

Keywords

Search

Navigation